MSD Korea’s fixed-dose combination product Delstrigo (doravirine·lamivudine·tenofovir disoproxil fumarate) will be listed with insurance benefit next month, at ₩19,491. Also, reimbursement for Takeda Korea’s Zejula cap. 100mg (niraparib) has been extended to cover monotherapy for ovarian cancer, upon which the price was cut by 6% and will be reimbursed at the price.

The Ministry of Food and Drug Safety held a Health Insurance Policy Deliberation Committee (HIPDC) meeting today and passed the ‘proposed amendment to the drug benefit list and price ceiling table.’ The amended list and table will be effective from October 1st.